Recommended dosage, dosage and taking time of the targeted drug Capmatinib (Touradida)

Capmatinib (Capmatinib) is a selective METtyrosine kinase inhibitor, mainly used to treat patients with MET exons Patients with advanced non-small cell lung cancer (NSCLC) with pan>14skipping mutations (METex14). The drug blocks tumor cell proliferation and migration by inhibiting the MET signaling pathway, thereby controlling tumor growth and delaying disease progression.

The conventional recommended dose for adult patients is 400 mg, taken orally twice a day, preferably at an interval of about 12 hours to maintain stable blood concentration. The medication may be taken with or without food, but to reduce gastrointestinal discomfort, it may be taken with food. No dose adjustment is required in patients with normal renal function or mild to moderate hepatic impairment, but caution should be used in patients with severe hepatic impairment.

It is recommended that the taking time of capmatinib be fixed at the same time every day to ensure regular taking and improve treatment compliance. For patients who need to be combined with other drugs (such as chemotherapy or immunotherapy), the medication time should be adjusted under the guidance of a doctor to avoid drug interactions that affect the efficacy. At the same time, the concurrent use of strong CYP3A inhibitors or inducers should be avoided to prevent abnormal plasma concentrations.

During capmatinib treatment, liver function, blood routine and electrolyte levels need to be monitored regularly, and changes in blood pressure and cardiac function need to be paid attention to. If serious adverse reactions occur, such as abnormal liver function, pulmonary symptoms or severe edema, you should seek medical treatment promptly and adjust the dose or discontinue the drug. Regular follow-up and evaluation of efficacy can help ensure drug safety and maximize treatment benefits.

Reference link:https://www.drugs.com